CN106963844B - Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia - Google Patents
Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia Download PDFInfo
- Publication number
- CN106963844B CN106963844B CN201710194477.1A CN201710194477A CN106963844B CN 106963844 B CN106963844 B CN 106963844B CN 201710194477 A CN201710194477 A CN 201710194477A CN 106963844 B CN106963844 B CN 106963844B
- Authority
- CN
- China
- Prior art keywords
- tomato
- saponin extract
- water
- soluble saponin
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000007688 Lycopersicon esculentum Nutrition 0.000 title claims abstract description 71
- 229930182490 saponin Natural products 0.000 title claims abstract description 61
- 150000007949 saponins Chemical class 0.000 title claims abstract description 60
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 59
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 240000003768 Solanum lycopersicum Species 0.000 title claims description 68
- 238000002360 preparation method Methods 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 5
- 108010059820 Polygalacturonase Proteins 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 34
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 34
- 229940116269 uric acid Drugs 0.000 abstract description 34
- 210000002966 serum Anatomy 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 241000227653 Lycopersicon Species 0.000 abstract 3
- 235000017709 saponins Nutrition 0.000 description 51
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 12
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 10
- 229950000193 oteracil Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 4
- CFOOYRCBRCGKFV-UHFFFAOYSA-N Esculeoside A Natural products CC1C2C(CC3C4CCC5CC(CCC5(C)C4CCC23C)OC6OC(CO)C(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9O)C8O)C(O)C6O)OC1%10NCC(COC%11OC(CO)C(O)C(O)C%11O)CC%10OC(=O)C CFOOYRCBRCGKFV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- VSQBWNYALURFOT-ZSFCQSFNSA-N esculeoside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@@]1([C@H](C[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CN1)OC(C)=O)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O VSQBWNYALURFOT-ZSFCQSFNSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000003953 Solanum lycopersicum var cerasiforme Nutrition 0.000 description 1
- 240000003040 Solanum lycopersicum var. cerasiforme Species 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- VEGRZKJXOJWSKN-QFCYIILWSA-N esculeoside B Natural products O(C[C@H]1C[C@@]2(O)O[C@@H]3[C@H]([C@H](C)[C@@H]2NC1)[C@]1(C)[C@H]([C@H]2[C@@H]([C@]4(C)[C@H](C[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O5)CC4)CC2)CC1)C3)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 VEGRZKJXOJWSKN-QFCYIILWSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- -1 saponin compounds Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229930003352 steroid alkaloid Natural products 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention discloses an application of a tomato water-soluble saponin extract in preparing a medicament or a health-care product for treating hyperuricemia. Through a large number of experiments, the applicant finds that the tomato water-soluble saponin extract from the tomato can effectively reduce the uric acid level in the serum, and can be used for preparing the medicines or health-care products for treating hyperuricemia and related diseases.
Description
Technical Field
The invention relates to an application of a tomato water-soluble saponin extract, in particular to an application of the tomato water-soluble saponin extract in preparing a drug or a health-care product for treating hyperuricemia.
Background
Uric acid is a product of purine metabolism in humans. There are two sources of human purines, endogenous dependent on self-synthesis or nucleic acid degradation (approximately 600mg/d), accounting for approximately 80% of total uric acid in the body; exogenous is an ingested purine diet (approximately 100mg/d) which accounts for approximately 20% of the total uric acid content in the body. Under normal conditions, the production and excretion of uric acid in a human body are basically kept in dynamic balance every day, and all factors influencing the production and excretion of blood uric acid can cause the increase of the blood uric acid level, thereby causing hyperuricemia. In recent years, some large-scale and prospective researches show that the rise of blood uric acid is in independent positive correlation with kidney diseases, atherosclerosis, essential hypertension, cerebral apoplexy, occurrence and death of cardiovascular events and the like. Hyperuricemia is one of the global important public health problems in the 21 st century, and is also an increasingly important metabolic disease problem in China, with the development of economic society and the change of dietary structure and life style in China, the prevalence rate of hyperuricemia is expected to increase by times in decades in the future, and patients will exert great pressure on society and families, so that the research of effective methods for preventing and treating hyperuricemia has important significance.
Tomatoes are vegetables which are eaten by people in daily life and contain high content of water-soluble saponin compounds. The university of Japan bear university academician of pharmacy in 2004, namely Tenuiongzhongxiong, Malayan hong, and the like, first obtains two steroid alkaloid saponins with complex structures, namely tomato saponin A (Esculeoside A) and tomato saponin B (Esculeoside B), from a Japanese tomato called Tatarian, namely tomato Temple, named as Tetrahedron 2004, 60: 4915-4920. The tomato saponin A (Esculeoside A) is the main saponin component in the tomato, and the content of the tomato saponin A (Esculeoside A) in the raw material is 3 times of that of the lycopene. Through further pharmacological activity research, the tomato saponin A and aglycone thereof (ESCulogenin A) are found to inhibit the formation of foam cells in vitro, are good acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors, and are promising anti-atherosclerosis compounds (Arterioscler Thromb Vasc biol.2007,27: 2400-2406). However, no report that the tomato water-soluble saponin extract can be applied to treatment or prevention of hyperuricemia is found at present.
Disclosure of Invention
The invention aims to solve the technical problem of providing the application of the tomato water-soluble saponin extract in preparing the medicine or health-care product for treating hyperuricemia.
The technical scheme of the invention is as follows: application of water-soluble tomato saponin extract in preparing medicine or health product for treating hyperuricemia is provided.
In the above technical scheme, the tomato water-soluble saponin extract can be prepared by adopting the existing conventional technology, and preferably, the preparation method of the tomato water-soluble saponin extract in the present application comprises: pulping fresh tomato, performing enzymolysis, filtering the enzymolysis liquid, collecting the filtrate, and drying to obtain the tomato water-soluble saponin extract crude product. In the enzymolysis, the used enzyme is usually pectinase, and the dosage of the pectinase is 0.04-0.06% of the weight of the raw materials.
The prepared tomato water-soluble saponin extract crude product has a better effect of treating hyperuricemia only under the condition of larger dosage, and in order to reduce the dosage of the tomato water-soluble saponin extract during treatment, the preparation method of the tomato water-soluble saponin extract preferably further comprises a purification step. The purification steps are methods which are conventionally used in the prior art and can purify saponin substances, such as resin column chromatography or silica gel column chromatography and other operations, and in the application, the specific purification steps are as follows: and (3) carrying out macroporous resin column chromatography or silica gel column chromatography on the tomato water-soluble saponin extract crude product, eluting with 80-100% ethanol by volume concentration, recovering the solvent, and drying to obtain the purified tomato water-soluble saponin extract. Wherein the macroporous resin can be D101 type, AB-8 type or Diaion HP20 type. The purified water-soluble tomato saponin extract obtained by the purification step has a tomato saponin A content of greater than or equal to 17%.
Furthermore, the invention also provides a medicine or health-care product for treating hyperuricemia, which is prepared by taking the water-soluble saponin extract of the tomato as an active ingredient. The dosage form of the medicine or the health care product can be pharmaceutically acceptable dosage forms, such as conventional dosage forms of capsules, tablets or granules.
Through a large number of experiments, the applicant finds that the tomato water-soluble saponin extract from the tomato can effectively reduce the uric acid level in the serum, and can be used for preparing the medicines or health-care products for treating hyperuricemia and related diseases.
Detailed Description
The effect of the water-soluble saponin extract of tomato in reducing the uric acid level in serum is further illustrated by the following experiments.
First, preparation of medicine and experimental scheme
1. Preparation of water-soluble tomato saponin extract
1) Selecting 1000g of ripe and non-rotten fresh cherry tomato fruits, cleaning, and smashing into juice by a blender; adding pectinase which is 0.05 percent of the weight of the fresh fruits, uniformly stirring, and carrying out enzymolysis and clarification at the temperature of 60 ℃ for 2 hours;
2) roughly filtering the enzymolysis solution with 100-mesh filter cloth, centrifuging the rough filtrate for 10min by a centrifugal machine at the rotation speed of 4000r/min, and pouring out supernatant after separation;
3) d101 type macroporous adsorption resin (resin consumption is 0.05 times of raw material amount, adsorption flow rate is 3BV/h) is put on the supernatant, then the resin column is washed by deionized water until effluent liquid is clear, then the effluent liquid is eluted by ethanol with the volume 5 times of the column volume and 100% (flow rate is 9BV/h), and eluent is collected;
4) placing the eluate in a rotary evaporator, recovering ethanol under reduced pressure at 0.05Mpa and 60 deg.C, further concentrating under reduced pressure at 0.07Mpa to obtain extract, vacuum drying the extract in a vacuum drying oven at vacuum degree of 0.09Mpa and temperature of 60 deg.C, and pulverizing to obtain total saponins of fructus Lycopersici Esculenti 2.7g with yield of 0.27%.
Detecting the content of saponin monomer tomato saponin A in the tomato water-soluble saponin extract to be 23.83% by an evaporation light scattering-high-efficiency liquid chromatography (chromatographic condition: a chromatographic column ZORBAX SB-C18 column, column temperature of 30 ℃, mobile phase of methanol-water gradient elution, detection time of 20min, flow rate of 0.8mL/min, sample injection amount of 10 muL, evaporation light scattering detector parameters of drift tube temperature of 100 ℃ and air flow rate of 2.7L/min).
2. Action of water-soluble tomato saponin extract on normal mouse blood uric acid
Taking 48 SPF-level Kunming mice, randomly dividing into 4 groups according to body weight, and dividing each group into 12 mice, namely a normal control group (distilled water), a low-dose group (100mg/kg) of tomato water-soluble saponin extract, a medium-dose group (200mg/kg) of tomato water-soluble saponin extract and a high-dose group (400mg/kg) of tomato water-soluble saponin extract. Mice were acclimatized for 1 week and then administered for 14 days. Each group was administered by gavage 1 time a day in the morning in a volume of 0.2ml/10 g. After the last administration, blood was collected and serum was separated, and the blood uric acid level was measured.
3. Action of tomato water-soluble saponin extract on hyperuricemia induced by potassium oxonate and hypoxanthine mouse blood uric acid
Taking 60 SPF-level Kunming mice, randomly dividing into 5 groups according to body weight, and dividing each group into 12 mice, namely a normal control group (distilled water), a hyperuricemia model group (distilled water), a tomato water-soluble saponin extract low dose group (100mg/kg), a tomato water-soluble saponin extract medium dose group (200mg/kg) and a tomato water-soluble saponin extract high dose group (400 mg/kg). Mice were acclimatized for 1 week and then administered for 14 days. Each group was administered by gavage 1 time a day in the morning in a volume of 0.2ml/10 g. At 14d, except for the normal control group, the other groups were injected subcutaneously with Potassium Oxonate (100mg/kg) and intraperitoneally with hypoxanthine (200mg/kg) and blood was collected 2 hours later to isolate serum and determine the uric acid level.
4. Effects of tomato water-soluble saponin extract on hyperuricemia induced by potassium oxonate and uric acid in mice with hyperuricemia
Taking 60 SPF-level Kunming mice, randomly dividing into 5 groups according to body weight, and dividing each group into 12 mice, namely a normal control group (distilled water), a hyperuricemia model group (distilled water), a tomato water-soluble saponin extract low dose group (100mg/kg), a tomato water-soluble saponin extract medium dose group (200mg/kg) and a tomato water-soluble saponin extract high dose group (400 mg/kg). Mice were acclimatized for 1 week and then administered for 14 days. Each group was administered by gavage 1 time a day in the morning in a volume of 0.2ml/10 g. At 14d, except for the normal control group, the other groups were molded by subcutaneous injection of Potassium Oxonate (100mg/kg) and intraperitoneal injection of uric acid (300mg/kg), and blood was collected 2 hours later to separate serum and determine the uric acid level.
Second, experimental results
1. Action of water-soluble tomato saponin extract on normal mouse blood uric acid
As shown in table 1, compared with the normal control group, the low, medium and high dosage groups of the water-soluble saponin extract of tomato have no significant difference in blood uric acid, which indicates that the water-soluble saponin extract of tomato has no influence on blood uric acid of normal mice.
TABLE 1 Effect of water-soluble saponin extract of Lycopersicon esculentum on blood uric acid in Normal mice: (
n＝12)
Note: compared with the normal control group, # p <0.05, # p < 0.01.
2. Action of tomato water-soluble saponin extract on hyperuricemia induced by potassium oxonate and hypoxanthine mouse blood uric acid
As shown in Table 2, compared with the normal control group, the blood uric acid level of the model group is obviously increased and has statistical significance (P is less than 0.01), which indicates that the hyperuricemia animal model is successfully modeled. Compared with a hyperuricemia model group, the tomato water-soluble saponin extract has low content, the medium dosage group has low content of blood uric acid, but the statistical significance is not achieved; the high-dose group of the tomato water-soluble saponin extract has the statistical significance (P is less than 0.01) for reducing the blood uric acid, which indicates that the tomato water-soluble saponin extract has the effect of reducing the uric acid of hyperuricemia model mice induced by the combination of potassium oxonate and hypoxanthine.
TABLE 2 Effect of water soluble saponin extract of Lycopersicon esculentum on Potassium Oxonate and hypoxanthine induced hyperuricemia mice blood uric acid ((
n＝12)
Note: compared with the normal control group, # p <0.05, # p < 0.01;
p <0.05, P <0.01 compared to model group.
3. Effects of tomato water-soluble saponin extract on hyperuricemia induced by potassium oxonate and uric acid in mice with hyperuricemia
As shown in Table 3, compared with the normal control group, the blood uric acid level of the model group is obviously increased and has statistical significance (P is less than 0.01), which indicates that the hyperuricemia animal model is successfully modeled. Compared with a hyperuricemia model group, the decrease of the blood uric acid in the tomato water-soluble saponin extract and a high-dose group has statistical significance (P is less than 0.01 or P is less than 0.05), which indicates that the tomato water-soluble saponin extract has the effect of reducing the uric acid for a hyperuricemia model mouse induced by the combination of potassium oxonate and uric acid.
TABLE 3 Effect of tomato Water soluble saponin extract on Potassium Oxonate and uric acid induced hyperuricemia mice blood uric acid ((
n＝12)
Note: compared with the normal control group, # p <0.05, # p < 0.01;
p <0.05, P <0.01 compared to model group.
Claims (2)
1. The application of the water-soluble saponin extract of the tomato in the preparation of the medicine for treating the hyperuricemia; wherein the content of the first and second substances,
the preparation method of the tomato water-soluble saponin extract comprises the following steps: pulping fresh tomato, performing enzymolysis with pectinase, filtering the enzymolysis solution, collecting filtrate, and drying to obtain a tomato water-soluble saponin extract crude product; carrying out macroporous resin column chromatography on the tomato water-soluble saponin extract crude product, eluting with 80-100% ethanol by volume concentration, recovering the solvent, and drying to obtain a purified tomato water-soluble saponin extract;
the administration dosage of the tomato water-soluble saponin extract is 400 mg/Kg.
2. Use according to claim 1, characterized in that: in the purified tomato water-soluble saponin extract, the content of the tomato saponin A is more than or equal to 17 percent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710194477.1A CN106963844B (en) | 2017-03-28 | 2017-03-28 | Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710194477.1A CN106963844B (en) | 2017-03-28 | 2017-03-28 | Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106963844A CN106963844A (en) | 2017-07-21 |
| CN106963844B true CN106963844B (en) | 2021-01-12 |
Family
ID=59336104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710194477.1A Active CN106963844B (en) | 2017-03-28 | 2017-03-28 | Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106963844B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109954043A (en) * | 2019-04-30 | 2019-07-02 | 广西壮族自治区农业科学院 | A method of the extraction purification saponin(e from cherry tomato |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804122B (en) * | 2010-04-09 | 2012-01-25 | 广西壮族自治区中国科学院广西植物研究所 | Tomato water-soluble saponin extract and preparation method and application thereof |
| US10183052B2 (en) * | 2015-02-13 | 2019-01-22 | Green4Health B.V. | Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions |
-
2017
- 2017-03-28 CN CN201710194477.1A patent/CN106963844B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106963844A (en) | 2017-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2829275B1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
| RU2294208C2 (en) | Using treated ginseng extract and saponins isolated from its | |
| CN104825500B (en) | Ganoderma leucocontextum extract, extraction method and application thereof | |
| WO2019052310A1 (en) | Total flavonoids extract of gynura formosana kitam. , preparation method therefor and use thereof for treating hyperuricemia | |
| CN101185671B (en) | Anti-tumor medicine extracted from Juglans regia and preparation method thereof | |
| CN108191616B (en) | Monomer component with selective butyrylcholine esterase inhibition effect in bletilla striata and application thereof | |
| CN106822331B (en) | Application of litchi rind extract mainly containing latticed polymer polyphenol in preparing medicine for treating hyperuricemia | |
| CN112168833A (en) | Timosaponin enzymolysis product and medical application of timosaponin AIII as main component thereof | |
| CN111714486B (en) | Application of polyacetylene compound | |
| CN106963844B (en) | Application of tomato water-soluble saponin extract in preparation of drug or health-care product for treating hyperuricemia | |
| CN110893197A (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| CN104873570B (en) | A kind of method for extraction and purification of Prunella vulgaris general flavone and its application | |
| CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
| CN110917181B (en) | Separation method and application of licochalcone B | |
| CN108314620B (en) | Sapium sebiferum elements I and J, and pharmaceutical composition and application thereof | |
| Hao et al. | Solid-state fermentation of Aspergillus Niger to optimize extraction process of Isoliquiritigenin from Glycyrrhiza uralensis | |
| CN110960569A (en) | Phyllanthus emblica extract and preparation method and application thereof | |
| CN109276637B (en) | Semen allii tuberosi extract, preparation method thereof and application thereof in preparing liver-protecting medicine | |
| CN108143787A (en) | A kind of preparation method of the compound flavones of pueraria lobata, hoveniae semoveniae semen | |
| CN109223739B (en) | Composition and preparation method and application thereof | |
| CN106822071B (en) | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same | |
| CN102824385B (en) | Aralia tengyuch euonymus bark total saponin and preparation method and application thereof | |
| CN113116935A (en) | Toad skin sterene total lactone extract and its preparation method and use | |
| CN104688798A (en) | Gypsophila oldhamiana Miq extractive preparation method and application | |
| KR20200063588A (en) | Black ginseng extract with increased anti-cancer component contents, method for manufacturing thereof, and anti-cancer composition comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210930 Address after: 511500 building J02, headquarters building, Tianan Zhigu science and Technology Industrial Park, No. 18, Chuangxing Avenue, high tech Industrial Development Zone, Qingyuan City, Guangdong Province Patentee after: Qingyuan Zhongda innovative drug research center Address before: 541006 the Guangxi Zhuang Autonomous Region Yanshan town Yanshan District, Guilin City, Yanshan Street No. 85 Patentee before: GUANGXI INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220606 Address after: 511500 No. 03, 2nd floor, No. J02, 1st-3rd floor, headquarters building, Tianan Zhigu science and Technology Industrial Park, No. 18, Chuangxing Avenue, high tech Industrial Development Zone, Qingyuan City, Guangdong Province Patentee after: Qingyuan Xinqing Pharmaceutical Technology Co.,Ltd. Address before: 511500 building J02, headquarters building, Tianan Zhigu science and Technology Industrial Park, No. 18, Chuangxing Avenue, high tech Industrial Development Zone, Qingyuan City, Guangdong Province Patentee before: Qingyuan Zhongda innovative drug research center |